表紙
市場調查報告書
商品編碼
1077248

吸入麻醉的全球市場 - 2022年∼2029年

Global Inhalation Anesthesia Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球吸入麻醉市場相關調查,提供市場概要,以及各類型,各用途,各終端用戶,各地區趨勢,競爭情形,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球吸入麻醉市場調查手法和範圍

第2章 全球吸入麻醉市場-市場定義和概要

第3章 全球吸入麻醉市場-摘要整理

  • 各類型,市場明細
  • 各用途,市場明細
  • 各終端用戶,市場明細
  • 各地區,市場明細

第4章 全球吸入麻醉市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球吸入麻醉市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 法規分析

第6章 全球吸入麻醉市場-COVID-19分析

第7章 全球吸入麻醉市場-各類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各類型
    • 市場魅力指數,各類型
  • 地氟醚
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 七氟醚
  • 異氟醚
  • 其他

第8章 全球吸入麻醉市場-各用途

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各用途
    • 市場魅力指數,各用途
  • 引進
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 維持

第9章 全球吸入麻醉市場-各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各終端用戶
    • 市場魅力指數,各終端用戶
  • 醫院
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 門診病人手術中心
  • 診所
  • 其他

第10章 全球吸入麻醉市場-各地區

  • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年),各地區
    • 市場魅力指數,各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球吸入麻醉市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 全球吸入麻醉市場-企業簡介

  • Troikaa Pharmaceuticals Ltd
  • Cardinal Health
  • ABBVIE Inc
  • Baxter International Inc
  • Fresenius SE & Co.KGaA
  • Halocarbon Products Corporation
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Piramal Enterprises Ltd

第13章 全球吸入麻醉市場-DataM

目錄
Product Code: DMPH5000

Market Overview

The global inhalation anesthesia market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

During surgical procedures, anesthetic drugs manage pain, respiration, blood pressure, blood flow, and heart rate and rhythm. Inhalational anesthesia is mostly used for sedation and induction of general anesthesia. Sevoflurane, desflurane, and nitrous oxide are inhalational anesthetics most often used. Respiratory depression, decreased arterial blood pressure, cerebral metabolic demand, and increased blood flow are common side effects of inhalational anesthetics.

Market Dynamics

The rapidly aging population, afflicted with cancer, cardiovascular, spinal, orthopedic, respiratory, gastrointestinal, neurological, and other diseases and disorders, is expected to drive growth. The growing number of orthopedic procedures, such as ligament and soft tissue repair, is also contributing to the expansion of daycare ambulatory surgeries, which is expected to increase the use of inhalation anesthesia. Furthermore, an increase in emergency cases and accidents is expected to impact market growth during the forecast period positively.

An increase in the number of surgeries performed worldwide will drive the market growth

The market is expected to expand due to an increase in the number of surgeries performed worldwide. According to Sedana Medical's annual estimates, approximately 4.5-7.5 million people were ventilated and sedated worldwide in 2017. Furthermore, a growing population pool, an increase in the number of geriatrics susceptible to chronic diseases, rising demand for shorter hospital stays, and increased access to health services are other factors driving the growth of the inhalation anesthetics market.

Inhalation anesthetics are also commonly used in accident care, where intravenous administration is difficult in ambulatory settings. Rapid sequence induction of general anesthesia with tracheal intubation is used in emergency labors. As a result, the growing number of emergency cases worldwide is propelling the inhalation anesthetics market.

According to United Nations estimates, the global population of people aged 60 and up reached 962 million in 2017, more than doubling the figure of 382 million in 1980. Older adults are expected to more than double by 2050, reaching nearly 2.1 billion.Older people are at a higher risk of getting affected with the chronic disorders hence increasing the market for inhalation anesthesia.

The increase in the number of emergency and trauma cases and the growing patient preference for ambulatory daycare procedures will positively impact the growth of the inhalation anesthesia industry. Access to universal health insurance coverage for a large population base, combined with continuous improvements in healthcare facilities, will provide additional growth opportunities. Furthermore, the advantages of inhalation anesthetics over injectable anesthetics will drive inhalation anesthesia business growth.

Inhalation anesthetic side effects is likely to hamper the market growth

However, inhalation anesthetic side effects, a lower adoption rate of inhaled anesthetics in certain surgical procedures, generic competition for almost all halogenated agents, and recent patent expirations are restraining the inhalation of the anesthetics market.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant effect on the anesthetic drug business. In the anesthetic drugs industry, manufacturing and supply chain difficulties include supplying medicines to end-users on time and managing shifting product demand.The market for general anesthesia drugs is seeing negative short-term growth. Due to a decline in product demand from key end-users, a shortage of procedures in most hospitals, a disrupted supply chain, and difficulties providing vital services due to lockdowns, the supply chain has been affected. To prepare for an impending increase in COVID-19-related inpatient hospital admissions and prevent the virus from spreading within health care institutions, non-essential surgical procedures were placed on hold as a first response.

The demand for surgical anesthetics has decreased as non-essential surgeries have decreased. On the other hand, hospitals have observed an unprecedented increase in critical care unit (ICU) patients during the COVID-19 pandemic. According to a study, 5-10% of COVID-19 patients with acute respiratory distress require long-term critical care (ARDS). These patients usually require large doses of sedatives and paralytics, which has increased demand for critical care drugs such as anesthetics, paralytics, opioids, and vasoactive agents, especially to assist ARDS ventilatory strategies. As a result, COVID-19 has had a minor impact on the anesthetic drug industry.

Segment Analysis

The sevoflurane segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The sevoflurane category accounted for most market share by product in 2018 and is predicted to increase rapidly shortly. This is due to several benefits it provides, including a favorable blood gas solubility coefficient and a pleasant odor and because of its therapeutic benefits and inexpensive cost, sevoflurane is the most extensively used inhalational anesthetic. Sevoflurane is a low-pungency ether inhalation anesthetic with a non-irritant odor and a low blood-gas partition coefficient. It has been discovered to be ideal for asthmatics and persons with sensitive airways. The medicine has taken over a large percentage of the market and is projected to continue to do so in the future.

In the United States, the product is also known as Sojourn, Ultane, and Ultane PEN, with Ultane being the most popular among all age groups. AbbVie is a major player in the market under consideration, and it sells Sevoflurane (marketed under the brand names Ultane and Sevorane) for human use worldwide.

Geographical Analysis

Asia-Pacific region holds the largest market share of the global inhalation anesthesia market

Asia-Pacific region is anticipated to dominate the inhalation anesthesia market, globally. This is due to increased diseases requiring surgery, such as cancer and respiratory illnesses. Furthermore, increased demand for healthcare infrastructure, an increase in the number of hospitals in emerging countries, a burgeoning R&D sector, increased healthcare reforms, and technological breakthroughs in the field of healthcare all contribute to market expansion in this region. According to an article published by the Bio Spectrum updated in April 2021, chronic diseases are one of the world's most serious health problems, costing the lives of an estimated 40 million people each year, 8.5 million of whom live in Asia. Cardiovascular illnesses, diabetes, cancer, and chronic respiratory disorders are the most frequent chronic diseases in the Asia Pacific. This is due to an aging population and bad lifestyle choices such as lack of physical activity and cigarette and alcohol consumption. Thus, the high prevalence of chronic diseases in the country increases the demand for surgeries thus driving the inhalation anesthesia market.

Furthermore, organic and inorganic tactics within key market players, such as mergers and acquisitions and alliances, would strengthen their product range in the studied industry, driving the market. In addition, multiple product releases will result in profitable market expansion. For instance, in June 2020, Piramal Urgent Care (PCC) has established a strategic partnership with Medivant Healthcare, a US-based pharmaceutical outsourcing facility, to help hospitals throughout the country solve the critical shortage of injectable drugs. Furthermore, advancements in various inhalation anesthesia from established key players, in the Asia-Pacific, are likely to drive the market growth in Asia-Pacific region

Competitive Landscape

The inhalation anesthesia market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Cardinal Health, ABBVIE Inc, Baxter International Inc, Fresenius SE&Co .KGaA, Halocarbon Products Corporation, Jiangsu Hengrui Medicine Co Ltd, Piramal Enterprises Ltd, Troikaa Pharmaceuticals Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the inhalation anesthesia market globally. For instance, In January 2019, Sandoz, a Novartis business, has launched desflurane Liquid for inhalation. In the United States, it is the first generic form of Suprane to be released. In inpatient and outpatient surgery patients, this liquid is utilized as an inhalation agent to maintain and induce anesthesia.

Key Developments

In April 2020,Hikma Pharmaceuticals PLC, an international generic pharmaceutical company, has launched Vecuronium Bromide for Injection, 10mg in the United States through Hikma Pharmaceuticals USA Inc., its US affiliate.

In July 2021,Hikma Pharmaceuticals PLC (Hikma), an international pharmaceutical company, has introduced Succinylcholine Chloride Injection, USP 20mg/mL in the United States through Hikma Pharmaceuticals USA Inc, its US affiliate. It's used for tracheal intubation and skeletal muscle relaxation during surgery or mechanical ventilation, in addition to general anesthesia.

Troikaa Pharmaceuticals Ltd

Overview:

Troikaa Pharmaceuticals Ltd. is a multinational pharmaceutical corporation based in Ahmedabad, Gujarat, India.

Product Portfolio:

Sevotroy: Sevotroy is a fantastic Anti-HF formulation with high water content. In adult and pediatric patients undergoing inpatient and outpatient surgery, Sevotroy is used to induce and maintain general anesthesia. Troikaa created Sevotroy, a formulation with the optimal water content, to prevent Sevoflurane from degrading to hydrofluoric acid. It is made in Troikaa's state-of-the-art production plant, which ensures no impurities. Even contaminants allowed by the US Pharmacopoeia are not present in Sevotroy.

Why Purchase the Report?

Visualize the composition of the global inhalation anesthesia market segmentation by type, application, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global inhalation anesthesia market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global inhalation anesthesia market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global inhalation anesthesia market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Global Inhalation Anesthesia Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Inhalation Anesthesia Market-Market Definition and Overview

3. Global Inhalation Anesthesia Market- Executive Summary

  • 3.1. Market Snippet By Type
  • 3.2. Market snippet By Application
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Inhalation Anesthesia Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the number of emergency cases and surgical interventions
      • 4.1.1.2. Increasing access to health-care services and surgeries
      • 4.1.1.3. Rising prevalence of chronic diseases in geriatric population
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects caused by inhaler anesthesia drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Inhalation Anesthesia Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Inhalation Anesthesia Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Inhalation Anesthesia Market- By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Desflurane*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Sevoflurane
  • 7.4. Isoflurane
  • 7.5. Others

8. Global Inhalation Anesthesia Market- By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Induction*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Maintenance

9. Global Inhalation Anesthesia Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Clinics
  • 9.5. Others

10. Global Inhalation Anesthesia Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Inhalation Anesthesia Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Inhalation Anesthesia Market- Company Profiles

  • 12.1. Troikaa Pharmaceuticals Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cardinal Health
  • 12.3. ABBVIE Inc
  • 12.4. Baxter International Inc
  • 12.5. Fresenius SE & Co.KGaA
  • 12.6. Halocarbon Products Corporation
  • 12.7. Jiangsu Hengrui Medicine Co Ltd
  • 12.8. Novartis AG
  • 12.9. Piramal Enterprises Ltd

LIST NOT EXHAUSTIVE

13. Global Inhalation Anesthesia Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us